AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
2.585
+0.055 (2.17%)
At close: Apr 24, 2025, 4:00 PM
2.590
+0.005 (0.19%)
After-hours: Apr 24, 2025, 4:59 PM EDT
AbCellera Biologics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for AbCellera Biologics stock have an average target of 7.50, with a low estimate of 5.00 and a high estimate of 10. The average target predicts an increase of 190.14% from the current stock price of 2.59.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for AbCellera Biologics stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Keybanc | Keybanc | Buy Maintains $4 → $5 | Buy | Maintains | $4 → $5 | +93.42% | Apr 16, 2025 |
| Benchmark | Benchmark | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 3, 2025 |
| Stifel | Stifel | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +286.85% | Feb 28, 2025 |
| Keybanc | Keybanc | Buy Maintains $5 → $4 | Buy | Maintains | $5 → $4 | +54.74% | Jan 8, 2025 |
| Benchmark | Benchmark | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Nov 5, 2024 |
Financial Forecast
Revenue This Year
27.48M
from 28.83M
Decreased by -4.68%
Revenue Next Year
35.12M
from 27.48M
Increased by 27.77%
EPS This Year
-0.63
from -0.55
EPS Next Year
-0.66
from -0.63
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 52.5M | 63.0M | 72.5M | ||
| Avg | 27.5M | 35.1M | 54.7M | ||
| Low | 17.4M | 14.5M | 37.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 82.1% | 129.2% | 106.3% | ||
| Avg | -4.7% | 27.8% | 55.7% | ||
| Low | -39.5% | -47.2% | 6.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.48 | -0.48 | -0.79 | ||
| Avg | -0.63 | -0.66 | -0.81 | ||
| Low | -0.72 | -0.76 | -0.82 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.